Compare Ginkgo Bioworks Holdings Inc (DNA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Sanofi SA — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Sanofi SA trades at $43.02 (market cap $102.91B). The key difference: Sanofi SA is far larger — about 174.3× Ginkgo Bioworks Holdings Inc's market cap, and Sanofi SA pays a 5.6% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | SNY | |
|---|---|---|
Market Cap | $590.53M | $102.91B |
Sector | Health | Health |
52-Week High | $16.14 | $52.34 |
52-Week Low | $5.48 | $41.33 |
Enterprise Value | $627.78M | $119.39B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
SNY trades at $44.00, up 1.15% with a bullish technical signal. Recent FDA approvals for Sarclisa and Nexviazyme highlight pipeline strength. Q1 2026 EPS beat expectations at $1.10 versus $1.06. Revenue grew to $46.72B in 2025 with net income margin of 15.95%. Analyst consensus is mixed with 44% buy ratings. The stock shows solid profitability with ROE at 10.29% and manageable debt levels.
Outlook is positive driven by drug approvals and earnings beats, but EU antitrust probes pose regulatory risks. Valuation at P/E 19.51 is reasonable versus peers. Institutional sentiment is cautious with 52% hold ratings. Key catalysts include Q2 2026 results and Sarclisa commercial rollout. Risks include competition and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
